Xenetic Biosciences Inc.

NASDAQ: XBIOHealthcare / Biotechnology / USA
1.87+0.0300+1.63%Vol 222 8781Y Perf -94.37%
Aug 21st, 2019 16:00
BID1.89 ASK1.97
Open1.88 Previous Close1.84
Pre-Market- After-Trading-
 - -%  - -%
Target Price
10.00 
Analyst Rating
— 0.00
Potencial %
434.76 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
★★ —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)2 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.62 
Earnings Date
16th Aug 2019

Today's Price Range

1.801.93

52wk Range

1.5454.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
14.72%
1 Month
-44.35%
3 Months
133.75%
6 Months
-13.82%
1 Year
-94.37%
3 Years
-60.21%
5 Years
-91.90%
10 Years
-

Name / TickerPriceChg.Chg.%
XBIO1.870.03001.63
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q03 2017--0.26-
Q02 2017--0.34-
Q01 2017--0.34-
Q04 2016--0.28-
Q02 2016--5.55-
Q01 2016--0.66-
----
----
Earnings Per EndEstimateRevision %Trend
12/2017 FY-0.890.00-
12/2018 FY-1.150.00-
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume222 878
Shares Outstanding (in ths.)871
Trades Count541
Dollar Volume442 820
Avg. Volume102 629
Avg. Weekly Volume288 804
Avg. Monthly Volume327 351
Avg. Quarterly Volume249 326
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Rating--Strong Buy
1.00

Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Further, company's proprietary drug development platform, PolyXen, enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company has ongoing business development activities to explore partnerships utilizing its PolyXen delivery platform.

CEO: Jeffrey F. Eisenberg

Teplephone: +1 781 778-7720

Address: 40 Speen Street, Framingham 01701, MA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

57%43%

Bearish Bullish

54%46%

Bearish Bullish

73%27%

News